NasdaqCM:HTGM

Stock Analysis Report

HTG Molecular Diagnostics

Executive Summary

HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine.


Snowflake Analysis

Excellent balance sheet and overvalued.


Similar Companies

Share Price & News

How has HTG Molecular Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HTGM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.6%

HTGM

9.4%

US Healthcare Services

12.5%

US Market


1 Year Return

-85.9%

HTGM

14.1%

US Healthcare Services

-12.7%

US Market

Return vs Industry: HTGM underperformed the US Healthcare Services industry which returned 14.1% over the past year.

Return vs Market: HTGM underperformed the US Market which returned -12.7% over the past year.


Shareholder returns

HTGMIndustryMarket
7 Day-0.6%9.4%12.5%
30 Day-41.1%-5.8%-14.7%
90 Day-51.3%-4.7%-21.5%
1 Year-85.9%-85.9%14.4%14.1%-10.9%-12.7%
3 Year-94.5%-94.5%59.0%58.3%12.6%5.4%
5 Yearn/a33.7%32.6%31.9%17.5%

Price Volatility Vs. Market

How volatile is HTG Molecular Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is HTG Molecular Diagnostics undervalued compared to its fair value and its price relative to the market?

0.91x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HTGM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HTGM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HTGM is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: HTGM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HTGM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HTGM is good value based on its PB Ratio (0.9x) compared to the US Healthcare Services industry average (2.8x).


Next Steps

Future Growth

How is HTG Molecular Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-5.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HTGM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HTGM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HTGM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HTGM's revenue (15.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: HTGM's revenue (15.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HTGM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has HTG Molecular Diagnostics performed over the past 5 years?

5.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HTGM is currently unprofitable.

Growing Profit Margin: HTGM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HTGM is unprofitable, but has reduced losses over the past 5 years at a rate of 5.6% per year.

Accelerating Growth: Unable to compare HTGM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HTGM is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (23.3%).


Return on Equity

High ROE: HTGM has a negative Return on Equity (-80.51%), as it is currently unprofitable.


Next Steps

Financial Health

How is HTG Molecular Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: HTGM's short term assets ($41.4M) exceed its short term liabilities ($8.9M).

Long Term Liabilities: HTGM's short term assets ($41.4M) exceed its long term liabilities ($12.3M).


Debt to Equity History and Analysis

Debt Level: HTGM's debt to equity ratio (41.1%) is considered high.

Reducing Debt: HTGM had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: HTGM has a low level of unsold assets or inventory.

Debt Coverage by Assets: HTGM's debt is covered by short term assets (assets are 4.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HTGM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: HTGM has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -1.9% each year.


Next Steps

Dividend

What is HTG Molecular Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HTGM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HTGM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HTGM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HTGM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HTGM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

John Lubniewski (55yo)

0.92

Tenure

US$1,297,753

Compensation

Mr. John L. Lubniewski serves as Director at HTG Molecular Diagnostics, Inc. since April 2019. Mr. Lubniewski serves as President since April 2018 and served as Chief Operating Officer at HTG Molecular Dia ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD1.30M) is above average for companies of similar size in the US market ($USD605.16K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Johnson
Executive Chairman1yrUS$2.01m0.36% $71.5k
John Lubniewski
President0.92yrUS$1.30m0.22% $44.1k
Shaun McMeans
Senior VP of Finance & Administration8yrsUS$1.04m0.17% $34.7k
Laura Godlewski
VP of Finance & Principal Accounting Officer0.83yrno data0.028% $5.7k
Maureen Cronin
Senior VP & Chief Scientific Officer1.33yrsno datano data
Debra Gordon
Senior VP & Chief Legal Counsel8.75yrsUS$296.70kno data
Sam Rua
Senior Vice President of Regulatory Affairs & Quality Systems2yrsno datano data
Patrick Roche
Senior Vice President of Research & Development5.92yrsUS$507.38kno data
Byron Lawson
Senior VP & Chief Commercial Officer2.17yrsno data0.075% $14.9k
Laura Beggrow
President of Diagnosticsno datano datano data

2.0yrs

Average Tenure

58yo

Average Age

Experienced Management: HTGM's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Timothy Johnson
Executive Chairman1yrUS$2.01m0.36% $71.5k
John Lubniewski
President0.92yrUS$1.30m0.22% $44.1k
Harry George
Independent Director18.17yrsUS$83.88k0.063% $12.6k
Michelle Griffin
Independent Director1.58yrsUS$84.95kno data
Lee McCracken
Independent Director4.42yrsUS$85.13k0.0043% $860.6
Ann Hanham
Lead Independent Director1yrUS$113.88k0.0083% $1.7k
Donnie Hardison
Independent Director3.83yrsUS$86.38k0.017% $3.4k
James LaFrance
Independent Director4.25yrsUS$92.63k0.017% $3.4k
Fred Hirsch
Member of Scientific Advisory Board4yrsno datano data
James Gulley
Member of Scientific Advisory Board4yrsno datano data

3.9yrs

Average Tenure

60.5yo

Average Age

Experienced Board: HTGM's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38.4%.


Top Shareholders

Company Information

HTG Molecular Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: HTG Molecular Diagnostics, Inc.
  • Ticker: HTGM
  • Exchange: NasdaqCM
  • Founded: 1997
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$19.968m
  • Shares outstanding: 58.40m
  • Website: https://www.htgmolecular.com

Number of Employees


Location

  • HTG Molecular Diagnostics, Inc.
  • 3430 East Global Loop
  • Tucson
  • Arizona
  • 85706
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HTGMNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMay 2015
65HDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2015

Biography

HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company’s assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL Cell of Origin Assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA Whole-Transcriptome Assay; HTG EdgeSeq DLBCL Cell of Origin Assay EU; HTG EdgeSeq ALKPlus Assay EU; HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assay; and HTG EdgeSeq Precision Immuno-Oncology Panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; governing agreement with QIAGEN Manchester Limited; development and professional services agreement with Invetech PTY Ltd; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 04:14
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.